NCT05277337View on ClinicalTrials.gov

Study Comparing Treatment With Alluzience vs Reconstituted Toxin

PHASE4CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

February 4, 2022

Primary Completion Date

October 12, 2022

Study Completion Date

October 12, 2022

Conditions
Glabellar Frown Lines
Interventions
BIOLOGICAL

Alluzience

Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection

BIOLOGICAL

powder BoNT-A (BOTOX/Vistabel)

Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection

Trial Locations (8)

40212

Galderma Research Site 2001, Düsseldorf

40545

Galderma Research Site 2002, Düsseldorf

44791

Galderma Research Site 2003, Bochum

EH10 4BE

Galderma Research Site 1003, Edinburgh

W1G 9PF

Galderma Research Site 1004, London

Galderma Research Site 1006, London

W1W 7JF

Galderma Research Site 1001, London

BA16 0HY

Galderma Research Site 1002, Street

Sponsors

Lead Sponsor

Galderma R&D
All Listed Sponsors
lead

Galderma R&D

INDUSTRY